I must admit that the latest ann re prc has me thinking... The...

I must admit that the latest ann re prc has me thinking...

The Chinese pharma industry is one of the fastest growing in the world (10-20% per year for many years) at a time when Western pharma are trading at lower P/Es. China is now 3rd largest market for pharmaceuticals, growing middle class, with better wages and a growing health insurance sector. So... the latest patent protection in china?

Could we be seeing a strategic move into China by a Western company that has been pulling strings in contract negatiations.

Or might this make invion more attractive to Chinese big bio?

ALso the wording of the latest release has subtly changed re operations, away from the inclusion of the company sell-off liquidation/firesale wording re ferghana. Looks like alot of posters missed this. I am encouraged somewhat by the omission of words. I know this would have been included somewhat to reassure investors, been very carefully worded, and I think GC does read HC. But this wasn't a cut and paste, and I think its important the company keep us informed even if it is with very vague updates such as this. It gives the market a sense that they are working on it.